Inhibitors of NLRP3 inflammasome
US11702391B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 23, 2022 |
| Grant date | Jul 18, 2023 |
| Priority date | — |
| Expiry date | Mar 23, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds of Formula I: that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.